重大事件即時報告 8-K 2026-06-24

MapLight Therapeutics 8-K 公告股東年會投票結果，董事選舉及審計任命均獲通過

AI 繁中摘要

MapLight Therapeutics 提交 8-K 申報，報告 2026 年股東年會投票結果 📋

2026 年 6 月 23 日，MapLight Therapeutics 舉行年度股東大會。截至記錄日期，已發行股份總數為 42,610,079 股，其中 36,883,750 股（約 86.56%）親身或由代理人出席。

會議審議了兩項提案：

**第一項：選舉三名董事，任期至 2029 年股東年會。**
- Martin Babler：31,424,194 票贊成，3,575,737 票 withheld，經紀人非投票 1,883,819
- Troy Cox：34,979,012 票贊成，20,919 票 withheld
- George Pavlov：34,220,342 票贊成，779,589 票 withheld
所有候選人均順利當選 ✅

**第二項：批准聘任 RSM US LLP 為 2026 財政年度（截至 2026 年 12 月 31 日）獨立註冊會計師事務所。**
- 贊成：36,859,217 票
- 反對：22,332 票
- 棄權：2,201 票
決議獲得通過 ✅

整體投票結果顯示股東對現任管理層及審計安排高度支持，未有重大異議。此 8-K 申報屬常規企業管治更新，對公司日常營運及財務報告穩定性具正面信號。投資者可關注後續研發及商業化進展。

展開英文正文

8-K

 false 0001770069 0001770069 2026-06-23 2026-06-23 
  
  
 UNITED STATES
 SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549
  
  

 FORM 8-K
  
  

 CURRENT REPORT
 Pursuant to Section 13 or 15(d)
 of the Securities Exchange Act of 1934
 Date of Report (Date of earliest event reported): June 23, 2026
  
  

 MapLight Therapeutics, Inc.
 (Exact name of registrant as specified in its charter)
  
  

  

Delaware
 
001-42914
 
83-2163243

(State or other jurisdiction
of incorporation)
 
(Commission
File Number)
 
(IRS Employer
Identification No.)
  

800 Chesapeake Drive

Redwood City, California 94063

(Address of principal executive offices)
 Registrant’s telephone number, including area code: (617) 984-6300
 N/A
 (Former name or former address, if changed since last report.)
  
  

 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
  

☐
 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

  

☐
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

  

☐
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

  

☐
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 Securities registered pursuant to Section 12(b) of the Act:
  

 Title of each class

 
 Trading
symbol(s)

 
 Name of each exchange
on which registered

Voting Common Stock, $0.0001 par value per share
 
MPLT
 
Nasdaq Global Select Market
 Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 Emerging growth company ☒
 If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
  
  
  

 

Item 5.07
 Submission of Matters to a Vote of Security Holders. 

 On June 23, 2026, MapLight Therapeutics, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”). At the Annual Meeting, the stockholders considered two proposals, each of which is described in more detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 29, 2026 (the “Proxy Statement”). Of the 42,610,079 shares outstanding as of the record date, 36,883,750 shares, or approximately 86.56%, were present or represented by proxy at the Annual Meeting. Set forth below are the results of the matters submitted for a vote of stockholders at the Annual Meeting. 
 Proposal No. 1: Election of three nominees to serve as directors until the 2029 annual meeting of stockholders and until their respective successors are elected and qualified. The votes were cast as follows: 
  

 Name

  
Votes For
 
  
Votes Withheld
 

 Martin Babler

  
 
31,424,194
 
  
 
3,575,737
 

 Troy Cox

  
 
34,979,012
 
  
 
20,919
 

 George Pavlov

  
 
34,220,342
 
  
 
779,589
 

 Broker Non-Votes: 1,883,819 
 All nominees were elected. 
 Proposal No. 2: Ratification of the selection of RSM US LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. The votes were cast as follows: 
  

 
  
Votes For
 
  
Votes Against
 
  
Abstained
 

 Ratification of selection of RSM US LLP

  
 
36,859,217
 
  
 
22,332
 
  
 
2,201
 

 Broker Non-Votes: 0 

 

 SIGNATURES 
 Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 
  

 

 
MapLight Therapeutics, Inc.

Dated: June 24, 2026
 

 
By:
 
 /s/ Christopher A. Kroeger

 

 

 
Christopher A. Kroeger, M.D.

 

 

 
Chief Executive Officer